company background image
FYB

Formycon XTRA:FYB Stock Report

Last Price

€75.30

Market Cap

€1.2b

7D

-2.0%

1Y

1.8%

Updated

31 May, 2023

Data

Company Financials +

FYB Stock Overview

Formycon AG develops and markets biosimilar products in Germany and Switzerland.

FYB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth6/6
Past Performance2/6
Financial Health1/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Formycon AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Formycon
Historical stock prices
Current Share Price€75.30
52 Week High€94.10
52 Week Low€63.80
Beta1
1 Month Change7.57%
3 Month Change-3.95%
1 Year Change1.76%
3 Year Change219.07%
5 Year Change101.88%
Change since IPO746.07%

Recent News & Updates

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

Nov 05
We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

Recent updates

We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

Nov 05
We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) Earnings

We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Sep 04
We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash Wisely

Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Jul 13
Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)

Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Jun 02
Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimates

Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

May 23
Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn Situation

Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

Feb 01
Here's Why We're Not At All Concerned With Formycon's (ETR:FYB) Cash Burn Situation

We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

Sep 25
We Think Formycon (ETR:FYB) Can Easily Afford To Drive Business Growth

We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

May 19
We're Interested To See How Formycon (ETR:FYB) Uses Its Cash Hoard To Grow

Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?

Jan 04
Is Formycon's (ETR:FYB) 179% Share Price Increase Well Justified?

Shareholder Returns

FYBDE BiotechsDE Market
7D-2.0%1.1%-0.1%
1Y1.8%-4.6%-8.5%

Return vs Industry: FYB exceeded the German Biotechs industry which returned -5.5% over the past year.

Return vs Market: FYB exceeded the German Market which returned -8.2% over the past year.

Price Volatility

Is FYB's price volatile compared to industry and market?
FYB volatility
FYB Average Weekly Movement7.2%
Biotechs Industry Average Movement6.6%
Market Average Movement5.0%
10% most volatile stocks in DE Market10.0%
10% least volatile stocks in DE Market2.7%

Stable Share Price: FYB is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: FYB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1999137Stefan Glombitzahttps://www.formycon.com

Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company’s pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials.

Formycon AG Fundamentals Summary

How do Formycon's earnings and revenue compare to its market cap?
FYB fundamental statistics
Market Cap€1.21b
Earnings (TTM)€35.99m
Revenue (TTM)€42.50m

33.6x

P/E Ratio

28.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FYB income statement (TTM)
Revenue€42.50m
Cost of Revenue€30.43m
Gross Profit€12.07m
Other Expenses-€23.92m
Earnings€35.99m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.24
Gross Margin28.41%
Net Profit Margin84.69%
Debt/Equity Ratio11.4%

How did FYB perform over the long term?

See historical performance and comparison